Who is sponsoring NCT04366622?

NCT04366622 is sponsored by Bayer.

What condition does NCT04366622 study?

NCT04366622 studies Clinical Pharmacology.

What drugs are being tested in NCT04366622?

Interventions: Riociguat (Adempas, BAY 63-2521).

What is the status of NCT04366622?

NCT04366622 is currently COMPLETED.

Last reviewed 2020-04-29 · How we verify

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

NCT04366622 PHASE1 COMPLETED

BAY 63-2521 is intended to be used for a disease that affects the blood flow through the lungs. Renal impairment is a common condition in patients with this disease. The goal of the study is to learn more about the safety of BAY 63-2521, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as a single oral dose of 1 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight

Details

Lead sponsor	Bayer
Phase	PHASE1
Status	COMPLETED
Enrolment	32
Start date	Wed Apr 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Sep 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Clinical Pharmacology

Interventions

Riociguat (Adempas, BAY 63-2521)

Countries

Germany